Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| Wainzua recommended for approval in the EU | 21 Oct 2024 |
| AstraZeneca licenses lipid lowering Lp(a) asset | 7 Oct 2024 |
| Total Voting Rights | 1 Oct 2024 |
| Tagrisso US approval in unresectable lung cancer | 26 Sept 2024 |
| Final OS results reported for TROPION-Breast01 | 23 Sept 2024 |
| Fasenra recommended for EU approval in EGPA | 23 Sept 2024 |
| FluMist approved for self-administration in US | 20 Sept 2024 |
| Fasenra EGPA US FDA approval | 18 Sept 2024 |
| Director/PDMR Shareholding | 13 Sept 2024 |
| Total Voting Rights | 2 Sept 2024 |
| Imfinzi approved in US for resectable lung cancer | 16 Aug 2024 |
| Total Voting Rights | 1 Aug 2024 |